Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
Michelle Kokkinou, Elaine E. Irvine, David R. Bonsall, et al.
Molecular Psychiatry (2020) Vol. 26, Iss. 6, pp. 2562-2576
Open Access | Times Cited: 89

Showing 1-25 of 89 citing articles:

Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance
Oliver Howes, Ekaterina Shatalina
Biological Psychiatry (2022) Vol. 92, Iss. 6, pp. 501-513
Open Access | Times Cited: 152
The synaptic hypothesis of schizophrenia version III: a master mechanism
Oliver Howes, Ellis Chika Onwordi
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1843-1856
Open Access | Times Cited: 86
Schizophrenia: from neurochemistry to circuits, symptoms and treatments
Oliver Howes, Bernard R Bukala, Katherine Beck
Nature Reviews Neurology (2023) Vol. 20, Iss. 1, pp. 22-35
Closed Access | Times Cited: 50
PI3K/AKT signaling pathway: Molecular mechanisms and therapeutic potential in depression
Ningning Guo, Xin Wang, Muran Xu, et al.
Pharmacological Research (2024) Vol. 206, pp. 107300-107300
Open Access | Times Cited: 22
New Drug Treatments for Schizophrenia: A Review of Approaches to Target Circuit Dysfunction
Oliver Howes, Eleanor Dawkins, Maria Lobo, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 8, pp. 638-650
Open Access | Times Cited: 15
Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies
Nina Dedic, Heather Dworak, Courtney Zeni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13185-13185
Open Access | Times Cited: 78
Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
Christoph U. Correll, Kenneth S. Koblan, Seth C. Hopkins, et al.
Schizophrenia (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 70
Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders
Els F. Halff, Grazia Rutigliano, Anna Garcia-Hidalgo, et al.
Trends in Neurosciences (2022) Vol. 46, Iss. 1, pp. 60-74
Open Access | Times Cited: 59
New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics
Maria Lobo, Thomas Whitehurst, Stephen Kaar, et al.
Neuroscience & Biobehavioral Reviews (2021) Vol. 132, pp. 324-361
Open Access | Times Cited: 57
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics
Daisy L. Spark, Alex Fornito, Christopher J. Langmead, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia
Eric D. Achtyes, Seth C. Hopkins, Nina Dedic, et al.
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1543-1556
Open Access | Times Cited: 30
Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future
Scott M. Thompson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 83-95
Closed Access | Times Cited: 29
Narrative Review: Low-Dose Ketamine for Pain Management
Alessandro Riccardi, Mario Guarino, Sossio Serra, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 9, pp. 3256-3256
Open Access | Times Cited: 25
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Nina Dedic, Lien Wang, Éva Hajós‐Korcsok, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101883-101883
Open Access | Times Cited: 8
Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data
Spyridon Siafis, Virginia Chiocchia, Malcolm Macleod, et al.
Wellcome Open Research (2024) Vol. 9, pp. 182-182
Open Access | Times Cited: 8
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
Michele L. R. Heffernan, Lee W. Herman, Scott P. Brown, et al.
ACS Medicinal Chemistry Letters (2021) Vol. 13, Iss. 1, pp. 92-98
Open Access | Times Cited: 54
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Felipe V. Gomes, Anthony A. Grace
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4467-4467
Open Access | Times Cited: 44
Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials
Gia Han Le, Emily S. Gillissie, Taeho Greg Rhee, et al.
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 5, pp. 401-415
Closed Access | Times Cited: 16
Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies
Yuya Mizuno, Hulegar A. Abhishekh, Bhagyashree Bhaskar Bhat, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 11, pp. 1058-1069
Open Access | Times Cited: 16
IL‐1β/IL‐1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha‐Synuclein pathology in the olfactory bulb, substantia nigra and striatum
Haichen Niu, Qian Wang, Weiguang Zhao, et al.
Brain Pathology (2020) Vol. 30, Iss. 6, pp. 1102-1118
Open Access | Times Cited: 49
Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials
Kah Kheng Goh, Tzu‐Hua Wu, Chun-Hsin Chen, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 3, pp. 236-252
Closed Access | Times Cited: 39
Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia
Giulia Maria Giordano, Edoardo Caporusso, Pasquale Pezzella, et al.
Expert Review of Neurotherapeutics (2022) Vol. 22, Iss. 7, pp. 541-555
Open Access | Times Cited: 27
Emerging Treatments in Schizophrenia
Christoph U. Correll, Anissa Abi‐Dargham, Oliver Howes
The Journal of Clinical Psychiatry (2022) Vol. 83, Iss. 1
Open Access | Times Cited: 22
Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans
Seth C. Hopkins, Nina Dedic, Kenneth S. Koblan
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 32
Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856
Veronica Begni, Alice Sanson, Alessia Luoni, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4119-4119
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top